S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
The craze for Masters gnomes is growing. Little golf-centric statue is now a coveted collector item
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
CVE:MDP

Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis

C$7.75
-0.40 (-4.91%)
(As of 06/16/2021)
Today's Range
C$7.70
C$8.14
50-Day Range
C$7.75
C$7.75
52-Week Range
C$2.80
C$9.75
Volume
40,981 shs
Average Volume
68,619 shs
Market Capitalization
C$148.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$3.18

Medexus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
59.0% Downside
C$3.18 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
C$5,408 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.07 out of 5 stars

MDP stock logo

About Medexus Pharmaceuticals Stock (CVE:MDP)

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.

MDP Stock Price History

MDP Stock News Headlines

Medexus Pharmaceuticals (CVE:MDP) Shares Down 4.9%
Medexus Pharmaceuticals Inc (P731.BE)
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
See More Headlines
Receive MDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$3.18
High Stock Price Target
C$4.00
Low Stock Price Target
C$2.35
Potential Upside/Downside
-59.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$108.29 million
Cash Flow
C$0.62 per share
Book Value
C$0.38 per share

Miscellaneous

Free Float
N/A
Market Cap
C$148.54 million
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Kenneth d'Entremont
    CEO & Director
  • Mr. Roland Boivin
    Chief Financial Officer
  • Mr. Bill Poncy
    Sr. VP of Commercial Operations - United States
  • Mr. Brian Peters
    VP of Sales & Marketing - United States
  • Ms. Tina Byers CFA
    Exec. of Investor Relations
  • Mr. Michael Pine
    Sr. VP of Bus. Devel. & Strategy
  • Mr. Michael David Adelman (Age 50)
    Gen. Mang., U.S. Operations

MDP Stock Analysis - Frequently Asked Questions

Should I buy or sell Medexus Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDP shares.
View MDP analyst ratings
or view top-rated stocks.

What is Medexus Pharmaceuticals' stock price target for 2024?

2 analysts have issued 12 month price targets for Medexus Pharmaceuticals' stock. Their MDP share price targets range from C$2.35 to C$4.00. On average, they predict the company's stock price to reach C$3.18 in the next year. This suggests that the stock has a possible downside of 59.0%.
View analysts price targets for MDP
or view top-rated stocks among Wall Street analysts.

How have MDP shares performed in 2024?

Medexus Pharmaceuticals' stock was trading at C$7.75 at the start of the year. Since then, MDP shares have increased by 0.0% and is now trading at C$7.75.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Medexus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medexus Pharmaceuticals investors own include Gatekeeper Systems (GSI), Enghouse Systems (ENGH), Ag Growth International (AFN).

How do I buy shares of Medexus Pharmaceuticals?

Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:MDP) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners